title: Adjuvant Therapy Trials.
abstract: In 2015, ramucirumab and TAS-102 became the 10th and 11th drugs approved by the Food and Drug administration for the treatment of patients with colorectal cancer, not counting leucovorin, and yet only 3 agents, 5-fluorouracil, capecitabine, and oxaliplatin, have proven benefit in adjuvant treatment. In fact, there have been no additions (and 1 subtraction levamisole) to our arsenal of therapies for patients with stages II and III colon cancer for more than a decade. How did we get here? Are we stuck? And how do we move forward?
authors.affiliation: From the Gastrointestinal Oncology, University of California, San Francisco, CA.
authors.forename: Carling
authors.initials: C
authors.lastname: Ursem
authors.forename: Katherine
authors.initials: K
authors.lastname: Van Loon
authors.forename: Alan
authors.initials: A
authors.lastname: Venook
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D006801:Humans; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D059039:Standard of Care; D016896:Treatment Outcome